Roxifiban acetate | CAS#176022-59-6 | fibrinogen Receptor Antagonist

MedKoo Cat#: 596766 | Name: Roxifiban acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Roxifiban acetate is a fibrinogen Receptor Antagonist

Chemical Structure

Roxifiban acetate

CAS#176022-59-6

Theoretical Analysis

MedKoo Cat#: 596766

Name: Roxifiban acetate

CAS#: 176022-59-6

Chemical Formula: C23H33N5O8

Exact Mass: 507.2329

Molecular Weight: 507.54

Elemental Analysis: C, 54.43; H, 6.55; N, 13.80; O, 25.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Roxifiban acetate; DMP 754; DMP-754; DMP754;

IUPAC/Chemical Name

methyl (S)-2-((butoxycarbonyl)amino)-3-(2-((R)-3-(4-carbamimidoylphenyl)-4,5-dihydroisoxazol-5-yl)acetamido)propanoate acetate

InChi Key

WDEMHBVIYZGQCD-KALLACGZSA-N

InChi Code

InChI=1S/C21H29N5O6.C2H4O2/c1-3-4-9-31-21(29)25-17(20(28)30-2)12-24-18(27)11-15-10-16(26-32-15)13-5-7-14(8-6-13)19(22)23;1-2(3)4/h5-8,15,17H,3-4,9-12H2,1-2H3,(H3,22,23)(H,24,27)(H,25,29);1H3,(H,3,4)/t15-,17+;/m1./s1

SMILES Code

O=C(OC)[C@H](CNC(C[C@H]1CC(C2=CC=C(C(N)=N)C=C2)=NO1)=O)NC(OCCCC)=O.CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 507.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Christen JR, Soubrier C, Martinez E, Roumieu V, Darmon O, Scandaliaris S, Picou L, Cuisset T, Grados A, Bernit E, Ebbo M, Harlé JR, Schleinitz N. [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor]. Rev Med Interne. 2017 Nov;38(11):769-773. doi: 10.1016/j.revmed.2017.05.013. Epub 2017 Jul 6. French. PubMed PMID: 28690092. 2: Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. Biochemistry. 2009 Sep 8;48(35):8355-65. doi: 10.1021/bi900475k. PubMed PMID: 19640007. 3: Barrett YC, Ebling W, Pieniaszek H, Billheimer J, Seiffert D. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist. J Pharm Biomed Anal. 2007 Aug 15;44(4):938-46. Epub 2007 Mar 31. PubMed PMID: 17485191. 4: Mousa SA. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Blood Coagul Fibrinolysis. 2007 Jan;18(1):55-60. PubMed PMID: 17179828. 5: Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost. 2007 Mar;5(3):542-50. Epub 2006 Dec 13. PubMed PMID: 17166246. 6: Mousa SA, Ahmad S. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Am J Hematol. 2007 Apr;82(4):276-82. PubMed PMID: 17039513. 7: Mousa SA, Bozarth JM, Seiffert D, Feuerstein GZ. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Blood Coagul Fibrinolysis. 2005 Apr;16(3):165-71. PubMed PMID: 15795533. 8: Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs. 2003;3(2):101-12. PubMed PMID: 14727937. 9: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PubMed PMID: 14685303. 10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):653-82. PubMed PMID: 14671684. 11: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97. PubMed PMID: 14571286. 12: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. PubMed PMID: 12949633. 13: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408. PubMed PMID: 12851663. 14: Serebruany VL, Malinin AI, O'connor CM, Gurbel PA; Roxifiban Oral Compound Kinetics Evaluation Trial-I Platelet Substudy. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J. 2003 Jul;146(1):91-8. PubMed PMID: 12851613. 15: Seiffert D, Thomas BE, Bradley JD, Munzer DA, Tchinnes MA, Kornhauser DM, Cain VA, Hua TA, Feuerstein GZ, Martin DE, Stern AM. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets. 2003 May;14(3):179-87. PubMed PMID: 12850842. 16: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. Review. PubMed PMID: 12743628. 17: Shi G, Lloyd TL, Sy SK, Jiao Q, Wernicki A, Mutlib A, Emm TA, Unger SE, Pieniaszek HJ Jr. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. J Pharm Biomed Anal. 2003 Apr 1;31(5):937-51. PubMed PMID: 12684106. 18: Pedicord DL, Dicker I, O'Neil K, Breth L, Wynn R, Hollis GF, Billheimer JT, Stern AM, Seiffert D. CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists. Thromb Haemost. 2003 Mar;89(3):513-21. PubMed PMID: 12624636. 19: Seiffert D, Pedicord DL, Kieras CJ, He B, Stern AM, Billheimer JT. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists. Thromb Res. 2002 Nov 1;108(2-3):181-9. PubMed PMID: 12590956. 20: Billheimer JT, He B, Spitz SM, Stern AM, Seiffert D. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy. Thromb Res. 2002 Sep 15;107(6):303-17. PubMed PMID: 12565717.